Ref: EPL/CS/SE/0029/2025

Date: May 22, 2025

To,

National Stock Exchange of India Limited	BSE Limited
Exchange Plaza, C-1, Block G,	P J Towers,
Bandra Kurla Complex, Bandra (East),	Dalal Street,
Mumbai - 400 051	Mumbai- 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Outcome of Board Meeting held on May 22, 2025.

In continuation to our letter dated May 13, 2025, and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), read with Schedule III of aforesaid regulation and SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November, 2024 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Thursday, May 22, 2025, has *inter-alia* transacted and approved/ recommended the following businesses:

1. Audited Financial Results (standalone and consolidated) for the quarter and year ended March 31, 2025.

In this regard, please find enclosed herewith:

a. Pursuant to Regulation 33 of the SEBI Listing Regulations, Audited Financial Results (Standalone & Consolidated) along with Audit Reports as at that date, issued by M/s. B S R & Co. LLP, Chartered Accountants, Auditors of the Company, a copy of which is enclosed herewith as **Annexure A**.

It is hereby declared that the Statutory Auditors of the Company have issued Audit Reports with 'Unmodified Opinion' on the Audited Financial Statements of the Company (Standalone and Consolidated) for the year ended March 31, 2025.

b. Press Release outlining key updates on the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2025, is also enclosed herewith as **Annexure B**.



Emcure Pharmaceuticals Limited

2. Dividend

Recommended a final dividend of Rs. 3/- (Rupees Three only) per equity share of Rs. 10/- (Rupees Ten only) each of the Company (at the rate of 30%) for the financial year ended March 31, 2025, subject to approval of the Members of the Company at the ensuing Annual General Meeting of the Company. Dividend, once approved by the Members, shall be paid within the prescribed timeline under the Companies Act, 2013.

3. Re-appointment of Dr. Mukund Gurjar (DIN: 00026843) as a Whole-time Director of the Company

Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the re-appointment of Dr. Mukund Gurjar (DIN: 00026843) as Whole-time Director of the Company for a further period of one (1) year commencing from August 28, 2025, subject to approval of Members in the ensuing Annual General Meeting of the Company.

Dr. Mukund Gurjar is not debarred from holding the office of a Director by virtue of any SEBI order and in accordance with BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 and NSE Circular No. NSE/CML/2018/02 dated June 20, 2018, or any such other authority, and that he is not related to any Director(s) or Key Managerial Personnel(s) of the Company.

The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the SEBI Listing Regulations are provided in **Annexure C**, enclosed herewith.

4. Appointment of Secretarial Auditors of the Company

The Board of Directors of the Company has approved the appointment of **M/s. SVD & Associates**, a Peer Reviewed Firm of Company Secretaries in Practice, Pune (Firm Registration Number: P2013MH031900), as the Secretarial Auditors of the Company for a period of five consecutive years commencing from the financial year 2025-26, subject to approval of Members in the ensuing Annual General Meeting of the Company.

The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the SEBI Listing Regulations are provided in **Annexure D**, enclosed herewith.



Emcure Pharmaceuticals Limited

5. Incorporation of a wholly-owned Subsidiary by the name "Emcure Generics Private Limited" in Pune, Maharashtra, India.

The Board of Directors of the Company approved the proposal for incorporation of a wholly-owned subsidiary company by the name "Emcure Generics Private Limited"

The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the SEBI Listing Regulations are provided in **Annexure E**, enclosed herewith.

The meeting of the Board of Directors of the Company commenced at 1:20 p.m. (IST) and concluded at 2:15 p.m. (IST).

RMAC

You are requested to take the above information on your records.

Thanking you,

For Emcure Pharmaceuticals Limited

Chetan Sharma Company Secretary & Compliance Officer Membership Number: F8352

Encl: As above

Emcure Pharmaceuticals Limited

Annexure - A

BSR&Co.LLP

Chartered Accountants

8th floor, Business Plaza Westin Hotel Campus 36/3-B, Koregaon Park Annex Mundhwa Road, Ghorpadi Pune - 411 001, India Telephone: +91 (20) 6747 7300 Fax: +91 (20) 6747 7100

Independent Auditor's Report

To the Board of Directors of Emcure Pharamceuticals Limited Report on the audit of the Standalone Annual Financial Results

Opinion

We have audited the accompanying standalone annual financial results of Emcure Pharamceuticals Limited (hereinafter referred to as the "Company") for the year ended 31 March 2025, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

Attention is drawn to the fact that the figures for the guarter ended 31 March 2024, as reported in these standalone annual financial results have been approved by the Company's Board of Directors, but have not been subjected to audit since the Company got listed during the current year.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in b the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive loss and other financial information for the year ended 31 March 2025.

Basis for Opinion

8

Bus

12-R

Pune India ed Acco

8th Floor,

G 411001

ness Plaza

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for

otaPSR Stores to partie immediation by Party pregaon Park ership firm with Registration No. BA61223) converted into B S R & Co. LLP (a tership with LLP Registration No. AAB-8181) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbar - 400063 Page 1 of 3

Registered Office

Independent Auditor's Report (Continued)

Emcure Pharamceuticals Limited

preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control siness that we identify during our audit.



Independent Auditor's Report (Continued)

Emcure Pharamceuticals Limited

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

a. The standalone annual financial results include the results for the quarter ended 31 March 2025 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **B S R & Co. LLP** Chartered Accountants Firm's Registration No.:101248W/W-100022

Shishen

Partner Membership No.: 062343 UDIN:25062343BMOJBX1515

Pune 22 May 2025

Page 3 of 3

Particulars		Quarter ended		in million (unless otherwise stated Year Ended		
	31-Mar-25	31-Dec-24	31-Mar-24	31-Mar-25	31-Mar-24	
	Refer note 8	Unaudited	Refer note 8	Audited	Audited	
Income:						
Revenue from operations	12,781.88	10,288.13	9,025.46	43,819,24	34,976.55	
Other income (Refer note 7)	223.96	194.10	406.10	1,188.07	1,262.36	
Total income	13,005.84	10,482.23	9,431.56	45,007.31	36,238.91	
Expenses:						
Cost of materials consumed	3,650.12	3,509.07	2,989.00	13,079.75	10,878.18	
Purchases of stock-in-trade	2,598.29	1,753.05	1,403.39	8,257.02	3,768.48	
Changes in inventories of finished goods, work-in-progress and stock in	(168.59)	(476.90)	(814.07)	(1,262.65)	(1,017.00	
trade						
Employee benefit expenses	1,981_60	1,960.14	1,743.54	7,823,10	7,064.10	
Depreciation and amortisation expense	569.12	566.46	562.19	2,249.72	2,048.32	
Finance cost	240.69	199.29	394.64	1,129.62	1,660.92	
Other expenses	2,335.29	2,369.73	2,640.47	9,690.36	9,863.85	
Net (gain)/ loss on foreign currency transactions (Refer note 7)	(61.20)	(71.13)	64.52	(236.71)	(120.21	
Total expenses	11,145.32	9,809.71	8,983.68	40,730.21	34,146.64	
Profit before exceptional items and tax	1,860.52	672.52	447.88	4,277.10	2,092.27	
Exceptional items (refer note 3)	5	*	93.15	-	93.15	
Profit before tax	1,860.52	672.52	354.73	4,277.10	1,999.12	
Tax expense						
Current tax	635.90	65.29	64.06	1,127.07	385.81	
Deferred tax	(170.95)	105.19	0.89	(21.25)	4.97	
Total tax expenses	464.95	170.48	64.95	1,105.82	390.78	
Profit for the Period/Year	1,395.57	502.04	289.78	3,171.28	1,608.34	
Other comprehensive income						
Other comprehensive income/(loss) not to be reclassified to profit or loss	(10.71)	(1.50)	(51.24)	(16.21)	(71.35	
n subsequent period					(·	
- Income tax on above	2.70	0.37	(0.72)	4.08	17.96	
Other comprehensive income/(loss) for the period/year	(8.01)	(1.13)	(51.96)	(12.13)	(53.39	
Total comprehensive income for the period/year	1,387.56	500.91	237.82	3,159.15	1,554.95	
arnings per share (not annualised for the Quarters)						
Basic	7.37	2.65	1.60	16.95	8.89	
Diluted	7.37	2.65	1.60	16.95	8,89	
aid-up equity share capital (Face value per share : Rs.10)	1,894.83	1,894.32	1,811.52	1,894.83	1,811.52	
Other equity				28,348.81	17,539.45	



Emcure Pharmaceuticals Limited

Building A-202, Ganga Osian Square, Wakad, Pune - 411 057, Maharashtra, India. Phone : +91 20 - 35040000 / 66770000 Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail:corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251

Particulars As at 31.Mar-23 34.Mar-24 31.Mar-24 A. ASSETS Audited Audited A. ASSETS 21.900-current assets 928.30 1.4,598.47 Property, plant and equipment Capital work-in-progress 928.30 1.6,600. 2.723.96 2.620.9 Intragible assets 2.622.19 2.723.96 2.620.4 2.723.96 2.620.4 Intragible assets 2.627.95 2.620.4 1.660.0		t March 31, 2025	
31-Mar-2531-Mar-24AuditedAuditedAuditedAuditedAuditedAuditedAuditedAuditedCapital work-in-progress28.8.30Capital work-in-progress2.2.2.39Capital work-in-progress2.2.2.39Intragible assets2.2.2.39Intragible assets inter development6.2.2Intragible assets inter development6.2.2Intragible assets3.2.0.5.01Intragible assets1.0.3.0.2.0.5Intragible assets1.1.0.5.6.3Intragible assets1.1.0.5.6.3Intragible assets1.1.0.3.2.8Intragible assets1.1.0.3.2.8 <th>Dartinulare</th> <th>Acat</th> <th>₹ in millio</th>	Dartinulare	Acat	₹ in millio
AuditedAuditedA. ASSTS() Non-current assetsProcerty, plant and equipment14,598,47Castiat work-in-progress928.30fight-of-use assets2,729.59lintragble assets262.19intragble assets262.29intragble assets2,627.40intragble assets2,627.40intragble assets2,627.40intragble assets2,627.53intragble assets2,729.59intragble assets2,729.59intragble assets2,729.54intragble assets2,729.54intragble assets2,729.54intragble assets2,729.54intragble assets2,729.54intragble assets2,729.55intragble assets2,729.55intragble assets2,729.55intragble assets2,729.55intragble assets2,729.55intragble assets11,905.63intragble assets11,905.63intragble assets2,729.55intragble assets <td< th=""><th>Particulars</th><th></th><th></th></td<>	Particulars		
(1) Mon-current assets			the state of the s
(1) Mon-current assets	A ACCETC		
Property. plant and equipment. 14,938.47 14,282.1 Cantul work-in-progress. 928.30 1,062.00 Hinangbile assets 2,729.95 2,620.4 Hinangbile assets 262.31 272.95 Intransitional assets 262.32 272.95 Financial assets 6,776.53 6,80.0 III. Loand 3,205.81 418.83 III. Loand 3,205.81 418.83 III. On on-current financial assets 342.11 165.22 Other non-current financial assets 29,560.62 26,334.9 II. Card and cash sets (net) 342.11 165.22 Iotal non-current assets 29,560.62 26,334.9 II. Yand receivables 11,305.65 110.32.8 II. Yand receivables 11,305.65 110.32.8 IV. Card receivables 11,378.22 1,355.6 Other current financial assets 795.66 775.6 IV. Cher current financial assets 1,378.22 1,355.6 Other current financial assets 24,460.51 22,480.51 IV. Cher current financial			
Capital work-in-progress928.501.064.0Right-of-us assets2,223.952,263.0Intrangible assets under development62.822,23.8Intrangible assets under development62.822,23.8Intrangible assets under development6,776.536,840.0I) Investments6,776.536,840.0II) Other non-current financial assets312.40133.6III) Other non-current financial assets29,560.6226,334.97IOther non-current stasts29,560.6226,334.97Coursent assets11,905.63110.32.8III) Carrent assets31,032.811,032.8III) Carrent assets33.07202.5III) Carrent assets11,905.63110.32.8III) Carrent assets33.07202.5III) Carrent assets24,600.5121,238.0III) Carrent assets24,600.5121,238.0III) Carrent assets24,600.5121,238.0Other corrent financial assets3,384.881,153.54Other corrent financial assets3,384.881,153.54Other corrent financial liabilities28,460.5121,234.33Other equity30,243.6413,336.97Other equity28,468.811,753.54Other equity28,468.811,753.54Other equity28,468.811,753.54Other corrent financial liabilities28,50.028,50.43III hasse Labilities1,858.331,82.93III hasse Labilities1,72.943,85.93III hance if ha	Andrew Construction Construction Andrew Construction Construction	14.598.47	14,288,1
hight-of-use assets 2,229.06 2,229.06 1 1 222.33 222.33 Intangible assets 62.82 - i Investments 62.82 - i Totad on-current financial assets 132.02 62.83.89 investories 29.560.62 26.83.89 i Totade receivables 11.905.63 - i Totade receivables 11.905.63 - i Stade receivables 13.77 - ii Stade receivables 13.77 - iii Stade receivables 13.97 - iiiiiiii date receivables 13.97 - - iiiiiiiiiiiii assets 13.97 - -			1,064.03
Intangible assets under development62.82Financial assets62.82i) Investments62.82ii) Ioter non-current financial assets132.44iii) Otter non-current financial assets132.42Dotter non-current sasets23.205.51Other non-current assets23.205.60.6222.00000023.205.60.62(2) Current assets23.205.60.62Inventories10.381.83(2) Current assets10.381.83(2) Current assets11.905.63Inventories10.381.83(1) Tode receivables11.905.63(2) Current assets11.905.63(1) Tode receivables11.905.63(2) Current assets11.905.63(3) Coher current financial assets796.86(3) Coher current financial assets11.378.22(3) Coher current financial assets11.378.22(2) Current assets11.378.22(2) Current assets11.378.22(2) Current assets11.378.22(2) Current assets24.600.51Cother current assets24.600.51Cother current financial assets24.600.51Cother current financial assets24.600.51Cother quity30.243.81Cother quity1.804.83(1) Non-current financial liabilities2.26.91(1) Non-current financial liabilities2.26.92(3) Other current financial liabilities2.24.95.85(4) Other quity2.60.10(2) Current tabilities2.60.10(3) Other current financial liabilities <td></td> <td></td> <td>2,620.4</td>			2,620.4
Financial asets 6.776.53 6.840.0 i) Investments 3.205.81 4.48.0 ii) Other non-current financial assets 3.205.81 4.48.0 iii) Other non-current sasets 3.205.81 4.48.0 income tax assets (net) 34.20.3 4.72.9 income tax assets 29.560.62 26.334.9 (2) Current assets 10.381.83 7,702.7 financial assets 11.905.63 11.1032.8 i) Trade receivables 11.109.5.63 11.032.8 ii) Bank balances other than (ii) above 53.07 202.5 iv) Other current financial assets 1.378.22 1.355.6 Other current assets 1.378.22 1.355.6 Other current assets 24.600.51 22.243.32 otal current assets 24.600.51 22.434.32 otal current assets 24.600.51 24.243.33 iii) Other coprime financial assets 1.384.83 1.81.55 otal current assets 24.600.51 24.243.33 iii) Other coprime financial assets 1.384.83 1.81.55 <	Intangible assets		273.84
i) Investments 6,776.33 6,840.0 ii) Loons 3,205.51 443.83 iii) Other non-current financial assets 3,205.51 4,43.83 income tax assets (net) 442.03 472.93 Other non-current assets 29,560.62 26,33.49 (2) Current assets 10,381.83 7,702.7 Financial assets 10,381.83 7,702.7 Financial assets 11,905.63 11,052.83 ii) Tade receivables 3,302.03 202.55 ii) Cash and cash equivalents 8,450.07 202.55 ii) Cash and cash equivalents 8,450.07 202.55 ii) Cash and cash equivalents 11,905.63 21,105.03 iii) Cash and cash equivalents 8,450.07 202.55 Other current financial assets 13,782.27 13,555.55 Other current financial assets 24,600.51 22,136.00 Assets classified as held for sale - - otal current assets 24,600.51 22,84.50 cotal current assets 3,82.45 3,83.11,72.53.44 cotal	Intangible assets under development	62.82	
ii) Laans 3,205,81 438.8 iii) Other non-current financial assets 132.40 133.40 Income tax assets (net) 472.03 647.2.9 Other non-current assets 342.11 163.2 rotal non-current assets 29,560.62 26,334.9 (2) Current assets 10,381.83 7,702.7 Inventories 10,381.83 7,702.7 Financial assets 11,905.63 11,032.8 i) Trade receivables 11,905.63 11,032.8 ii) Eash and cash equivalents 84.90 118.7 iii) Bash balances other than (ii) above 33.07 202.5 vol ther current financial assets 1,378.22 1,355.6 Other current assets 24,600.51 21,224.33 col current inabilities <	Financial assets	1	
iii) Other non-current financial assets 132.40 133.40 Income tax assets (net) 472.03 472.03 Other non-current assets 29,560.62 26,334.97 Internent assets 29,560.62 26,334.97 (2) Current assets 10,381.83 7,702.7 Internent assets 10,956.63 11,032.87 (2) Current assets 11,905.63 11,032.87 (1) Trade receivables 11,905.63 11,032.87 (11) Trade receivables 11,905.63 11,032.87 (11) Trade receivables 11,905.63 11,032.87 (12) Trade receivables 13,772.27 1,355.67 (12) Other current financial assets 736.68 757.66 Other current assets 21,784.83 1,132.87 (2) Current assets 24,600.51 22,138.00 (2) Current assets 24,600.51 22,134.30 (2) Current assets 1,894.83 1,811.57 (2) Current assets 1,894.83 1,811.57 (1) Non-current financial liabilities 1,828.13 1,622.17 (1) Non-	i) Investments	6,776.53	6,840.0
Income tax assets (net) 472.03 472.93 Other non-current assets 342.11 163.2 fold non-current assets 29,660.62 26,334.9 (2) Current assets 10,381.83 7,702.7 Inventories 10,381.83 7,702.7 Financial assets 11,905.63 11,032.80 (1) Carrent assets 34.90 118.7 (1) Cach and cash equivalents 84.90 118.7 (1) Bank balances other than (i) above 53.07 202.55 (2) Other current financial assets 79.68.6 767.66 Other current assets 1,378.22 1,355.65 Other current assets 24,600.51 221,243.33 OTAL ASSETS 54,161.13 47,569.37 Other current financial assets 24,600.51 21,234.33 Other current financial isset 18,94.83 1,811.53 Equity share capital 1,894.83 1,811.53 Other ono-current financial liabilities 18,831.33 1,622.11 (1) Non-current financial liabilities 28,458.20 1,828.13 <t< td=""><td>ii) Loans</td><td>3,205.81</td><td>418.84</td></t<>	ii) Loans	3,205.81	418.84
Other non-current assets342.1116832fold non-current assets29,560.6226,334.93(2) Current assets10,381.837,702.7Financial assets11,955.6311,032.81(1) Tode recivables11,955.6311,032.81(1) Tode recivables33,07202.55(1) Tode recivables33,07202.55(1) Other current financial assets796.86767.60Other current assets1,778.221,355.6720 Other current financial assets24,600.51221,480.00Assets classified as held for saleOTAL ASSETS54,161.1347,569.30CIQUIY AND LABIUTIES1,894.831,811.57Equity share capital1,894.831,7,539.40Cit capital1,894.831,7,539.40Cit capital1,834.831,7,539.40Cit capital1,834.831,7,539.40Cit capital1,834.831,7,539.40Cit capital1,834.831,7,539.40Cit capital1,834.831,7,539.40Cit capital1,834.831,622.11Non-current liabilities2,840.801,622.13Provisions2,61.102,24.509,762.86Deferred tax liabilities (net)2,64.092,84.43Cit current liabilities1,77.751,873.33(a) Total outstanding dues of micro and small enterprises; and (b) Total outstanding dues of micro and small enterprise; and (c) Total outstanding dues of micro and small enterprise; and (c) Total outstanding dues of micro and sm	iii) Other non-current financial assets	182.40	193.49
International current assets 29,560.62 26,334.9 (2) Current assets 10,381.83 7,702.7 Financial assets 11,905.63 11,002.81 (1) Trade receivables 11,905.63 11,002.81 (1) Trade receivables 11,905.63 11,002.81 (1) Trade receivables 11,905.63 12,022.81 (1) Trade receivables 13,78.22 1,355.65 Other current financial assets 796.86 767.66 Other current assets 24,600.51 21,234.32 Otal current assets 24,600.51 21,234.32 Other equity 30,243.64 19,350.97 Other equity 30,243.64 19,350.97 (1) Non-current liabilities 1,894.83 1,811.57 (1) Non-current liabilities 1,894.83 1,821.55 (1) Non-current liabilities 1,894.83 1,822.91 (1) Non-current liabilities 1,838.13 1,622.17 (1) Non-current liabilities 1,838.13 1,622.17 (1) Non-current liabilities 2,956 2889.41 (1) Non-cur	Income tax assets (net)	472.03	472.9
(2) Current assets10,381.837,702.7Financial assets10,381.837,702.7Financial assets11,905.6311,032.8ii) Tade receivables11,905.6311,032.8iii) Cash and cash equivalents84.90118.7iii) Bankers off than (iii) above53.07720.55iv) Other current financial assets796.86767.60Other current assets1.378.221.355.65Other current assets1.378.221.355.65Other current assets24,600.5121,234.35OTAL ASSETS24,600.5121,234.35Cotal current assets24,600.5121,234.35OTAL ASSETS54,161.1347,569.30Equity share capital1,894.831,811.55Charle equity28,348.811,7339.45Ital equity30,243.6419,350.97Ital equity28,348.811,7339.45Ital equity266.1.01244.56ii) Loser Labilities1,283.831,622.17iii) Other non-current financial liabilities299.64388.93Provisions261.10244.56Deferred tax liabilities (net)264.09289.43ii) Detrowings2,495.309,762.85iii) Catel custanding dues of micro and small enterprises; and (liabilities1,77.75iii) Tatel custanding dues of micro and small enterprise; and (liabilities1,272.42iii) Tatel outstanding dues of micro and small enterprise; and (liabilities1,27.94.2iii) Tatel outstanding dues of micro and small enterprise; and (l	Other non-current assets	342.11	163.2
inventories 10,381.83 7,702.7 Financial assets 111,905.63 111,032.81 i) Cash and cash equivalents 84.90 1118.7 ii) Bank balances other than (ii) above 53.07 202.55 iv) Other current financial assets 778.68 7767.66 Other current financial assets 244,600.51 221,180.09 Assets classified as held for sale - 54.22 otal current assets 244,600.51 221,283.83 COTAL ASSETS 54,161.13 47,569.30 EQUITY AND LABILITIES 54,161.13 47,569.30 EQUITY AND LABILITIES 54,161.13 47,569.30 Cother equity 30,243.64 19,350.97 i) Borrowings 4,062.89 4,382.09 ii) Corrowings 4,062.89 4,382.09 iii) Corrowings 4,062.89 4,382.00 iii) Corrowings 2,101 224.54 Deferred ta: liabilities 1,383.13 1,622.17 iii) Other on-current financial liabilities 9,755.85 6,917.137 (2) Current Iiabilities 1,77.75 187.32 iii) Cother on-current financial liabilities 1,77.75 187.32 iii) Cother current financial liabilities 1,77.75 187.32 iii) Cotal outstanding dues of micro and small enterprises; and (a) Total outstanding dues of micro and small (a) Total outstanding dues of micro and small enterprises; and (b) Total outstanding dues of micro and small (b) Total outstanding dues of micro and small (c) To	Total non- current assets	29,560.62	26,334.97
Financial assets 11,905,63 11,905,63 11,905,63 11,905,73 11,915,75 11,915,7	(2) Current assets		
i) Trade receivables 11,905.63 11,032.81 ii) Cash and cash equivalents 84.90 118.7. iii) Bank balance other than (ii) above 53.07 2025.5 iv) Other current financial assets 795.86 775.66 Other current assets 1,378.22 1,355.67 Other current assets 24,600.51 22,180.06 Assets classified as held for sale - 54,22 otal current assets 24,600.51 22,234.32 OTAL ASSETS 54,161.13 47,569.36 c Equity Share capital 1,894.83 1,891.51 Equity share capital 1,894.83 1,891.53 Other equity 23,348.81 1,753.94 otal equity 23,348.81 1,753.94 Chronournent liabilities 1,894.83 1,820.57 III) Other one-current financial liabilities 2,996.4 388.05 III) Dear one-current liabilities 2,2495.30 9,762.86 III) Cher one-current financial liabilities 2,495.30 9,762.86 III) Lease Liabilities (net) 2,495.30 9,762.86 1,713.32 IIII) Cher one-current financial liabilities	Inventories	10,381.83	7,702.74
ii) Cash and cash equivalents 84.90 118.7. iii) Bank balances other than (ii) above 53.07 202.5. iv) Other current financial assets 796.68 787.66 Other current financial assets 1,378.22 1,355.65 Assets classified as held for sale - 54.22 otal current assets 24,600.51 21,284.33 OTAL ASSETS 54,161.13 47,559.30 .EQUITY AND LABILITIES - - Equity 30,243.64 19,350.97 .I.QUITY AND LABILITIES - - Equity share capital 1,894.83 1,891.35 .Other equity 30,243.64 19,350.97 .I.ABILITIES - - (1) Non-current liabilities - - Financial liabilities - - .ii) Current financial liabilities - - .ii) Cher non-current financial liabilities - - .iii) Other non-current financial liabilities - - .iii) Cher non-current financial liabilities - - <td>Financial assets</td> <td></td> <td></td>	Financial assets		
iii) Bark balances other than (ii) above 53.07 220.57 iv) Other current financial assets 796.86 767.60 Other current assets 1,378.22 1,355.67 Other current assets 24,600.51 221,234.33 otal current assets 24,600.51 221,234.33 OTAL ASSETS 54,24 34,7569.30 OTAL ASSETS 54,24 34,7569.30 OTAL ASSETS 54,24 34,7569.30 OTAL ASSETS 54,24 34,7569.30 Other current assets 24,600.51 221,234.33 Other current assets 54,04 34,7569.30 Other equity 28,348.81 17,599.43 Other equity 30,243.64 19,350.97 I.LIABULTES 4,062.89 4,382.00 (i) Non-current liabilities 1,838.13 1,622.17 iii) Other non-current financial liabilities 1,838.13 1,622.17 iii) Other non-current financial liabilities 1,838.13 1,622.17 iii) Other non-current financial liabilities 1,729.42 6,752.85 6,917.17 <t< td=""><td>i) Trade receivables</td><td>11,905.63</td><td>11,032.86</td></t<>	i) Trade receivables	11,905.63	11,032.86
iv) Other current financial assets 796.86 767.60 Other current assets 1,378.22 1,355.60 24,600.51 221,00.01 Assets classified as held for sale - 54,22 335.60 24,24,00.51 221,234.33 OTAL ASSETS 54,161.13 47,569.30 21,234.33 47,569.30 CTAL ASSETS 54,161.13 47,569.30 21,234.33 1,811.57 Equity Anro LABILITIES 1,894.83 1,811.57 26,348.81 17,539.45 Other current liabilities 1,894.83 1,811.57 28,348.81 17,539.45 Other current liabilities 1,894.83 1,811.57 28,348.81 17,539.45 Other current liabilities 1,894.83 1,811.57 28,348.81 17,539.45 Other current liabilities 1,935.67 28,348.81 17,539.45 34,382.05 I) Borrowings 4,062.89 4,382.05 34,382.05 34,382.05 34,382.05 34,382.05 34,382.05 34,382.05 34,382.05 34,382.05 34,382.05 34,382.05 34,382.05 34,382.05	ii) Cash and cash equivalents	84.90	118.73
Other current assets 1,378.22 1,378.22 1,378.22 Assets classified as held for sale 24,600.51 21,180.02 otal current assets 24,600.51 21,234.33 OTAL ASSETS 24,600.51 21,234.33 OTAL ASSETS 54,161.13 47,569.30 Equity capital 1,894.83 1,811.57 Equity share capital 1,894.83 1,7,539.43 Other equity 28,348.81 17,539.43 otal equity 30,243.64 19,350.97 tube context is abilities 1,838.13 1,622.17 i) Borrowings 4,062.89 4,382.00 ii) Lesse Liabilities 1,838.13 1,622.17 iii) Other non-current financial liabilities 299.64 388.90 Provisions 261.10 234.54 234.54 Other current liabilities 1,727.5 187.32 ii) Derowings 2,495.30 9,762.86 ii) Derowings 2,495.30 9,762.86 iii) Trade payables 1,77.5 187.32 iii) Trade payables	iii) Bank balances other than (ii) above	53.07	202.51
Assets classified as held for sale24,600.5121,180.02otal current assets24,600.5121,234.32OTAL ASSETS54,151.1347,569.30Equity AND LIABILITIES Equity Equity share capital Other equity1,894.831,811.57Other equity28,348.8117,539.43otal equity30,243.6419,350.97I. LABILITIES Financial liabilities4,062.894,382.09i) Borrowings4,062.894,382.09ii) Lease Liabilities (net)26,110234.55ji) Lease Liabilities6,725.856,917.17iii) Current liabilities1,77.75187.32iii) Lease Liabilities1,77.75187.32iii) Lease Liabilities1,77.75187.32iii) Lease Liabilities1,77.75187.32iii) Crurent liabilities1,72.941,755.26iii) Crurent liabilities1,77.75187.32iii) Crurent liabilities1,72.941,755.26iii) Crurent liabilities1,72.941,755.26iii) Cral outstanding dues of micro and small enterprises; and iv) Other current financial liabilities1,72.941,755.26Other current liabilities591.87927.25Provisions28.1424.56.0028.45.00iv) Other current liabilities591.87927.25Provisions28.1424.56.0028.94.26.00iv) Other current liabilities591.87927.25Provisions28.1424.56.00Income tax liabilities (net)71.20.1119	iv) Other current financial assets	796.86	767.60
Assets classified as held for sale24,600.5121,180.02otal current assets24,600.5121,234.32OTAL ASSETS54,151.1347,569.30Equity AND LIABILITIES Equity Equity share capital Other equity1,894.831,811.57Other equity28,348.8117,539.43otal equity30,243.6419,350.97I. LABILITIES Financial liabilities4,062.894,382.09i) Borrowings4,062.894,382.09ii) Lease Liabilities (net)26,110234.55ji) Lease Liabilities6,725.856,917.17iii) Current liabilities1,77.75187.32iii) Lease Liabilities1,77.75187.32iii) Lease Liabilities1,77.75187.32iii) Lease Liabilities1,77.75187.32iii) Crurent liabilities1,72.941,755.26iii) Crurent liabilities1,77.75187.32iii) Crurent liabilities1,72.941,755.26iii) Crurent liabilities1,72.941,755.26iii) Cral outstanding dues of micro and small enterprises; and iv) Other current financial liabilities1,72.941,755.26Other current liabilities591.87927.25Provisions28.1424.56.0028.45.00iv) Other current liabilities591.87927.25Provisions28.1424.56.0028.94.26.00iv) Other current liabilities591.87927.25Provisions28.1424.56.00Income tax liabilities (net)71.20.1119	Other current assets	1,378.22	1,355.67
Add controlAdd controlOTAL ASSETS54,161.1347,569.30COTAL ASSETS54,161.1347,569.30COTAL ASSETS54,161.1347,569.30Equity AND LIABILITIES1,894.831,811.57Equity Share capital1,894.831,811.57Other equity22,348.8117,539.45otal equity30,243.6419,350.97LIABILITIES1,807.081,838.131,622.17(1) Non-current liabilities1,838.131,622.17iii) Other non-current financial liabilities299.64388.93Provisions261.10234.56Deferred tax liabilities (net)264.09289.44Stal non-current liabilities2,95.309,762.86iii) Other non-current liabilities177.75187.32iii) Carrent liabilities2,495.309,762.86iii) Trade payables1,729.421,765.62(a) Total outstanding dues of micro and small enterprises; and (b) Total outstanding dues of micro and small enterprises; and (c) Other current liabilities591.87 292.72 291.73Other current liabilities591.87 292.7299.762.86 281.43Other current liabilities281.43 245.60income tax liabilities (net)712.01 712.01199.77Atal liabilities281.43 245.60245.60 272.72Other current liabilities (net)71			21,180.09
OTAL ASSETSOTAL ASSETSCOTAL ASSETS54,161.13COTAL ASSETS47,569.30Equity1,894.831,811.52Cother equity28,348.8117,539.42Other equity30,243.6419,350.92ctal equity30,243.6419,350.92LIABILITIES1,894.831,811.52(1) Non-current liabilities1,838.131,622.13ii) Dorrowings4,062.894,382.09iii) Other non-current financial liabilities299.64388.93Provisions261.10234.56Deferred tax liabilities (net)264.09289.44stal non-current liabilities6,725.856,917.17(2) Current liabilities177.75187.32iii) Tade payables1,77.75187.32(a) Total outstanding dues of micro and small enterprises; and (b) Total outstanding dues other than (2)(iii)(a) above (c) Transing (28.44)245.66Other current liabilities591.87927.25Provisions28.443245.66Income tax liabilities (net)17,191.6421,301.16tat liabilities17,191.6421,301.16tat liabilities23,917.4928,218.33	Assets classified as held for sale	525	54.24
EQUITY AND LIABILITIES Equity Equity Equity share capital Other equity 0 otal equity 30,243.64 1,894.83 1,1000 <td< td=""><td>Total current assets</td><td>24,600.51</td><td>21,234.33</td></td<>	Total current assets	24,600.51	21,234.33
EQUITY AND LIABILITIES Equity Equity Equity share capital Other equity 0 otal equity 30,243.64 1,894.83 1,1000 <td< td=""><td>TOTAL ASSETS</td><td>54,161,13</td><td>47.569.30</td></td<>	TOTAL ASSETS	54,161,13	47.569.30
Equity Equity share capital Other equity1,894.83 28,348.811,811.57 28,348.81Other equity30,243.6419,350.97ctal equity30,243.6419,350.97ctal equity30,243.6419,350.97ctal equity30,243.6419,350.97ctal equity30,243.6419,350.97ctal equity30,243.6419,350.97ctal equity30,243.6419,350.97ctal equity30,243.6419,350.97ctal equity30,243.6419,350.97ctal equity4,062.894,382.09ctal equity4,062.894,382.09ctal equity4,062.894,382.09ctal equity299.64388.90Provisions264.09289.42Deferred tax liabilities (net)264.09289.43ctal non-current liabilities2,495.309,762.85ctal equipses1,77.75187.32ii) Borrowings2,495.309,762.85ii) Lease Liabilities10,943.638,090.23iii) Trade payables1,729.421,765.62ctal enterprises; and10,943.638,090.23iv) Other current financial liabilities591.87927.25Provisions281.43245.60Income tax liabilities (net)712.01199.77ctal current liabilities (net)712.01199.77ctal current liabilities (net)712.01199.77ctal current liabilities (net)712.01199.77ctal current liabilities (net)712.01			
Equity share capital Other equity1,894.83 28,348.811,811.52 (28,348.81otal equity30,243.6419,350.92ctal equity30,243.6419,350.92ctal equity30,243.6419,350.92ctal equity30,243.6419,350.92ctal equity30,243.6419,350.92ctal equity30,243.6419,350.92ctal equity4,062.894,382.05ctal habilities4,062.894,382.05ii) Lease Liabilities1,622.171,622.17iii) Other non-current financial liabilities299.64388.93Provisions261.10234.55Deferred tax liabilities (net)264.09289.42otal non-current liabilities6,725.856,917.17iii) Lease Liabilities177.75187.32iii) Trade payables177.75187.32iii) Trade payables1,729.421,765.62Other current financial liabilities1,729.421,765.62Other current financial liabilities591.87927.25Provisions281.43245.66Income tax liabilities (net)712.01199.77tat current liabilities (net)712.01199.77tat liabilities17,193.6421,301.16tat liabilities23,917.4928,218.31tat liabilities23,917.4928,218.31tat liabilities23,917.4928,218.31tat liabilities23,917.4928,218.31tat liabilities23,917.4928,218.31tat liab			
Other equity28,348.8117,539.43otal equity30,243.6419,350.97t.IABILITIES30,243.6419,350.97(1) Non-current liabilities1,024.36419,350.97i) Borrowings4,062.894,382.05ii) Other non-current financial liabilities1,038.131,622.17iii) Other non-current financial liabilities299.64388.93Provisions261.10234.55Deferred tax liabilities (net)264.09289.42otal non-current liabilities6,725.856,917.17(2) Current liabilities2,495.309,762.26ii) Lease Liabilities177.75187.32iii) Trade payables117.75187.32iii) Trade payables10,943.638,090.23iv) Other current financial liabilities1,729.421,765.62Other current liabilities17,729.421,765.62iv) Other current financial liabilities17,29.43245.60iv) Other current financial liabilities17,29.421,765.62Other current liabilities281.43245.60iv) Other current financial liabilities17,191.6421,301.16ital current liabilities (net)712.01199.77ottal current		1,894.83	1,811.52
LIABILITIES (1) Non-current liabilities (1) Non-current liabilities 4,062.89 4,382.00 ii) Lease Liabilities 1,838.13 1,622.17 iii) Other non-current financial liabilities 299.64 388.93 Provisions 261.10 234.55 Deferred tax liabilities (net) 264.09 289.42 otal non-current liabilities 6,725.85 6,917.17 (2) Current liabilities 1,777.75 187.32 ii) Lease Liabilities 1,777.75 187.32 iii) Lease Liabilities 1,777.75 187.32 iii) Trade payables 10,943.63 8,090.23 (v) Other current financial liabilities 1,729.42 1,765.62 Other current liabilities 591.87 927.25 Provisions 281.43 245.60 Income tax liabilities (net) 712.01 199.77 ottal current liabilities (net) 712.01 199.77 ottal		28,348.81	17,539.45
(1) Non-current liabilities4,062.894,382.05i) Borrowings4,062.894,382.05ii) Lease Liabilities1,838.131,622.17iii) Other non-current financial liabilities299.64388.93Provisions261.10234.55Deferred tax liabilities (net)264.09229.42otal non-current liabilities6,725.856,917.17(2) Current liabilities6,725.856,917.17(2) Current liabilities2,495.309,762.85i) Borrowings2,495.309,762.85ii) Lease Liabilities1,77.751,87.32iii) Trade payables1,77.751,87.32(b) Total outstanding dues of micro and small enterprises; and (b) Total outstanding dues other than (2)(iii)(a) above iv) Other current financial liabilities1,729.421,765.62Other current liabilities2,91.749282.133245.66Income tax liabilities (net)712.01199.77tat labilities17,191.6421,301.16tat liabilities2,917.4928,218.33	otal equity	30,243.64	19,350.97
Financial liabilities4,062.894,382.09i)Borrowings1,838.131,622.17ii)Other non-current financial liabilities299.64388.93Provisions261.10234.55Deferred tax liabilities (net)264.09289.47otal non-current liabilities6,725.856,917.17(2) Current liabilities6,725.856,917.17(2) Current liabilities2,495.309,762.86ii)Lesse Liabilities1,77.75187.32iii) Trade payables1,77.75187.32(a) Total outstanding dues of micro and small enterprises; and (b) Total outstanding dues other than (2)(iii)(a) above10,943.638,090.23V) Other current liabilities1,729.421,765.62Other current liabilities591.87927.25Provisions281.43245.60Income tax liabilities (net)712.01199.77tat liabilities17,191.6421,301.66tat liabilities23,917.4928,218.33	. LIABILITIES		
i)Borrowings4,062.894,382.09ii)Lease Liabilities1,838.131,622.17iii)Other non-current financial liabilities299.64388.91Provisions261.10234.58Deferred tax liabilities (net)6,725.856,917.17otal non-current liabilities6,725.856,917.17(2) Current liabilities6,725.856,917.17ii)Borrowings2,495.309,762.85ii)Borrowings2,495.309,762.85ii)Lease Liabilities177.75187.32iii)Lease Liabilities260.23122.46(a) Total outstanding dues of micro and small enterprises; and (b) Total outstanding dues other than (2)(iii)(a) above10,943.638,090.23iv)Other current liabilities1,729.421,765.62Other current liabilities591.87927.25Provisions lncome tax liabilities (net)712.01199.77otal outrent liabilities71,191.6421,301.16tat liabilities17,191.6421,301.16tat liabilities23,917.4928,218.33	(1) Non-current liabilities		
ii) Lease Liabilities1,838.131,622,17iii) Other non-current financial liabilities299.64388.93Provisions261.10234.56Deferred tax liabilities (net)264.09289.42otal non-current liabilities6,725.856,917.17(2) Current liabilities6,725.856,917.17(2) Current liabilities2,495.309,762.86ii) Borrowings2,495.309,762.86iii) Lease Liabilities1177.75187.32iiii) Trade payables10,943.638,090.23(a) Total outstanding dues of micro and small enterprises; and (b) Total outstanding dues other than (2)(iii)(a) above iv) Other current financial liabilities10,943.638,090.23Other current liabilities591.87927.25Provisions 	Financial liabilities		
iii) Other non-current financial liabilities299.64388.99Provisions Deferred tax liabilities (net)261.10234.58Deferred tax liabilities (net)264.09289.42otal non-current liabilities6,725.856,917.17(2) Current liabilities Financial liabilities i) Borrowings2,495.309,762.85ii) Lease Liabilities (a) Total outstanding dues of micro and small enterprises; and (b) Total outstanding dues other than (2)(iii)(a) above iv) Other current financial liabilities10,943.638,090.23Other current financial liabilities Provisions Income tax liabilities (net)591.87 712.01927.25Other current liabilities (net)712.01199.77ottal current liabilities (net)17,191.6421,301.16ottal liabilities (norme tax liabilities (net)23,917.4928,218.33ottal liabilities (net)23,917.4928,218.33ottal liabilities17,191.6421,301.16ottal liabilities23,917.4928,218.33ottal liabilities23,917.4928,218.33ottal liabilities23,917.4928,218.33ottal liabilities17,191.6421,301.16ottal liabilities23,917.4928,218.33ottal liabilities23,917.4928,218.33ottal liabilities23,917.4928,218.33ottal liabilities23,917.4928,218.33ottal liabilities000ottal outstanding dues other than (non-current liabilities0ottal outstanding dues other than (non-cur	i) Borrowings	4,062.89	4,382.09
Provisions Deferred tax liabilities (net)261.10 234.58Deferred tax liabilities (net)6,725.85otal non-current liabilities Financial liabilities i) Borrowings6,725.85ii) Borrowings ii) Lease Liabilities (a) Total outstanding dues of micro and small enterprises; and (b) Total outstanding dues other than (2)(iii)(a) above iv) Other current financial liabilities10,943.63Other current liabilities Provisions Income tax liabilities (net)591.87 27.25Other current liabilities Income tax liabilities (net)17,191.64Other liabilities Income tax liabilities17,191.64Other current liabilities Income tax liabilities17,191.64Other current liabilities Income tax liabilities17,191.64Other current liabilities23,917.49Other current liabilities Income tax liabilities23,917.49Other current liabilities17,191.64Other current liabilities17,191.64<	ii) Lease Liabilities	1,838.13	1,622,17
Deferred tax liabilities (net)264.09289.42otal non-current liabilities6,725.856,917.17(2) Current liabilities2,495.309,762.85i) Borrowings2,495.309,762.85ii) Lease Liabilities177.75187.32iii) Trade payables177.75187.32(a) Total outstanding dues of micro and small enterprises; and (b) Total outstanding dues other than (2)(iii)(a) above10,943.638,090.23Other current liabilities1,729.421,765.62Other current liabilities591.87927.25Provisions Income tax liabilities (net)712.01199.77ottal uurrent liabilities17,191.6421,301.16utal liabilities17,191.6421,3	iii) Other non-current financial liabilities	299.64	388.91
Deferred tax liabilities (net)264.09289.42otal non-current liabilities6,725.856,917.17(2) Current liabilities2,495.309,762.85i) Borrowings2,495.309,762.85ii) Lease Liabilities177.75187.32iii) Trade payables177.75187.32(a) Total outstanding dues of micro and small enterprises; and (b) Total outstanding dues other than (2)(iii)(a) above10,943.638,090.23Other current liabilities1,729.421,765.62Other current liabilities591.87927.25Provisions Income tax liabilities (net)712.01199.77ottal uurrent liabilities17,191.6421,301.16utal liabilities17,191.6421,3	Provisions	261.10	234.58
(2) Current liabilitiesFinancial liabilitiesi) Borrowingsii) Lease Liabilities(a) Total outstanding dues of micro and smallenterprises; and(b) Total outstanding dues other than (2)(iii)(a) aboveiv) Other current financial liabilitiesOther current financial liabilitiesProvisionsIncome tax liabilities10,043.6311,729.4211,729.4211,729.4211,729.4211,729.4211,729.4211,729.4211,729.4211,729.4211,729.4211,729.4211,729.4211,729.4211,729.4211,729.4211,729.4211,729.4212,01111,729.4211,729.4211,729.4211,729.4211,729.4211,729.4211,729.4211,729.4211,729.4211,729.4211,729.4211,729.4211,729.4211,729.4211,729.4312,01112,01113,011.1623,917.4928,218.33		and the second se	289.42
Financial liabilities2,495.309,762.89i) Borrowings2,495.309,762.89ii) Lease Liabilities177.75187.32iii) Trade payables177.75187.32(a) Total outstanding dues of micro and small enterprises; and (b) Total outstanding dues other than (2)(iii)(a) above iv) Other current financial liabilities10,943.638,090.23Other current financial liabilities1,729.421,765.62Other current liabilities281.43245.60Income tax liabilities (net)712.01199.77otal current liabilities17,191.6421,301.16otal liabilities23,917.4928,218.33otal liabilities000	otal non-current liabilities	6,725.85	6,917.17
i) Borrowings 2,495.30 9,762.89 ii) Lease Liabilities 177.75 187.32 iii) Trade payables (a) Total outstanding dues of micro and small enterprises; and (b) Total outstanding dues other than (2)(ii)(a) above iv) Other current financial liabilities 1,729.42 1,765.62 Other current liabilities 991.87 9927.25 Provisions 281.43 245.60 Income tax liabilities (net) 712.01 199.77 etal current liabilities 201,7191.64 21,301.16 23,917.49 28,218.33	(2) Current liabilities		
ii) Lease Liabilities 177.75 187.32 iii) Trade payables (a) Total outstanding dues of micro and small enterprises; and (b) Total outstanding dues other than (2)(ii)(a) above iv) Other current financial liabilities 1,729.42 1,765.62 Other current liabilities 591.87 927.25 Provisions 281.43 245.60 Income tax liabilities (net) 712.01 199.77 otal current liabilities 2,17,191.64 21,301.16 23,917.49 28,218.33	Financial liabilities	1 1	
iii) Trade payables (a) Total outstanding dues of micro and small enterprises; and (b) Total outstanding dues other than (2)(iii)(a) above iv) Other current financial liabilities Other current liabilities Provisions Income tax liabilities (net) otal current liabilities tatal liabilities Description Descri	i) Borrowings	2,495.30	9,762.89
(a) Total outstanding dues of micro and small enterprises; and (b) Total outstanding dues other than (2)(iii)(a) above iv) Other current financial liabilities260.23 10,943.63122.48 8,090.23Other current financial liabilities10,943.638,090.23Other current liabilities1,729.421,765.62Provisions Income tax liabilities (net)281.43245.60Income tax liabilities17,191.6421,301.16Ital liabilities23,917.4928,218.33	ii) Lease Liabilities	177.75	187.32
enterprises; and (b) Total outstanding dues other than (2)(iii)(a) above iv) Other current financial liabilities Other current liabilities Provisions Income tax liabilities (net) otal current liabilities atal liabilities Description Truent liabilities Description Truent liabilities Truent liabilities Description Truent liabilities Truent liabilities	iii) Trade payables	1 1	
(b) Total outstanding dues other than (2)(iii)(a) above10,943.638,090.23iv) Other current financial liabilities1,729.421,765.62Other current liabilities591.87927.25Provisions281.43245.60Income tax liabilities712.01199.77ottal current liabilities17,191.6421,301.16atal liabilities23,917.4928,218.33		260.23	122.48
iv) Other current financial liabilities 1,729.42 1,765.62 Other current liabilities 591.87 927.25 Provisions 281.43 245.60 Income tax liabilities (net) 712.01 199.77 otal current liabilities 17,191.64 21,301.16 23,917.49 28,218.33			100 metri (1
Other current liabilities591,87927.25Provisions281.43245.60Income tax liabilities (net)712.01199.77otal current liabilities17,191.6421,301.16atal liabilities23,917.4928,218.33			
Provisions Income tax liabilities (net) 281,43 712.01 245,60 199,77 stal current liabilities 17,191.64 21,301.16 stal liabilities 23,917.49 28,218.33	v) Other current financial liabilities	1,729.42	1,765.62
Provisions Income tax liabilities (net) 281,43 712.01 245,60 199,77 stal current liabilities 17,191.64 21,301.16 stal liabilities 23,917.49 28,218.33	Other current liabilities	591.87	977 25
Income tax liabilities (net) 712.01 199.77 tal current liabilities 23,917.49 28,218.33		(0.2007) (g. 10027)	
tal liabilities 23,917.49 28,218.33			199.77
tal liabilities 23,917.49 28,218.33			



		K in millio
Particulars	Year Ended	Year Ended
	31-Mar-25	31-Mar-24
	Audited	Audited
A. Cash flows from operating activities:		
Profit before tax	4,277.10	1,999.1
Adjustment for:	2 240 72	2 040 2
Depreciation and amortisation expense Unrealised exchange loss	2,249.72	2,048.3
Finance costs	44.73 1,129.62	74.1 1,660.9
Employee share-based expense	1,125 82	38.5
Interest income from banks and others	(14.72)	(10.5
Interest income from intercorporate loans	(133.31)	(25.3
Gain on disposal of property, plant and equipment	(387,44)	(72.7
Gain on termination of leases	(63.47)	(20.7
Impairment of investment and loans given to related parties	(00147)	93.1
Dividend received from subsidiary		(530.0
	7,118.48	5,254.7
Norking capital adjustments:		
- (Increase) / decrease in inventories	(2,679.09)	(603.4
- (Increase) / decrease in trade receivables	(872.77)	(487.9)
- (Increase) / decrease in other financial assets	(19.25)	97.3
- (Increase) / decrease in other assets	(112.78)	77,3
- Increase / (decrease) in trade payables	2,991.15	1,478.3
- Increase / (decrease) in other financial liabilities	(100.03)	145.4
- Increase / (decrease) in other liabilities	(127.87)	485.1
- Increase / (decrease) in provisions	46,14	71.1
	(874.50)	1,263.6
ash generated from operating activities	6,243.98	6,518.3
		Sector and
Income tax paid (net of refunds)	(661.13)	(668.63
let cash generated from operating activities (A)	5,582.85	5,849.73
. Cash flows from investing activities		
	11 0 00 001	12 402 5
Purchase of property, plant and equipment, Leasehold Land and capital work-in-progress	(1,961,50)	(2,492.50
Purchase of intangible assets	(150,93)	(42.70
Proceeds from sale of property, plant and equipment, assets held for sale and transfer of	305.48	107.58
Leasehold Land rights		207 5
Proceeds against Assets held for sale Investment in Financial Instruments	(71.16)	207.5
Intercorporate loans & deposits given to subsidiaries	(3,659.60)	(57.39
Repayment of intercorporate loans & deposits by subsidiaries	901.98	23.7
Interest received from banks and others	18.77	14.9
Interest received on loans to subsidiaries	114.38	1.3
Dividend received		530.08
Term deposit placed	(17.61)	(14.8)
Term deposit matured	164.08	11.40
et cash used in investing activities (B)	(4,356.11)	{1,710.77
Cash flows from financing activities		
Proceeds from long-term borrowings		2,854.24
Repayment of long-term borrowings	(7,134.16)	(4,433.51
Intercorporate deposits taken from subsidiary	4,915.00	(4,435.51
Repayment of intercorporate deposits taken from subsidiary	(857.70)	
Proceeds from / (repayment) of short-term borrowings (net)	(3,842.00)	1,224.9
Repayment of Lease Liabilities	(371.30)	(317.08
Payment on account of settlement of Employee stock options	(072.00)	(202.3)
Proceeds from issue of shares (net of offer expenses)	7,792.28	76.5
Interest paid	(994.59)	(1,537.7)
Interim dividend paid		(361.70
Dividend paid on equity shares		(180.85
et cash generated from / (used in) financing activities (C)	(492.47)	(2,877.48
ct cash generated from / fused fr) mancing activities (c)	(452.47)	12,077.40
Net increase / (decrease) in cash and cash equivalents (A+B+C)	734,27	1,261.48
Cash and cash equivalent as at beginning of the period	(889.05)	(2,130.51
Effect of exchange rate fluctuations on cash and cash equivalent	(20.49)	(20.02
ish and cash equivalent as at period end	(175.27)	(889.09
manual of each and each any indext.	21 44 25	21 84 24
mponents of cash and cash equivalent:	31-Mar-25	31-Mar-24
Cash on hand Palances with bank in surrent accounts	0.26	0.37
Balances with bank in current accounts	84.64	118.34
Bank overdrafts used for cash management purpose	(260.17)	



Emcure Pharmaceuticals Limited

Statement of Audited Standalone Financial Results for the quarter and year ended March 31, 2025

Notes:

1. These audited standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 ("the Regulations").

2. The above audited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on May 22, 2025. The results are subjected to Limited review by the statutory auditors of the Company in terms of Regulation 33 of The Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR), as amended. The statutory auditors have expressed an unmodified opinion on above audited standalone financial results.

3. During the quarter ended March 31, 2024, the Company assessed the expected cash flows and the future plans of all its subsidiary Companies and accordingly, recorded provision for impairment of Rs. 1.90 million for investment in Emcure Nigeria Limited ("Nigeria"). The company also impaired outstanding balance given to Nigeria along with accrued interest amounting to Rs. 91.25 million. These impairment provisions were classified as exceptional items.

4. In accordance with Ind AS 108 "Operating Segments", segment information has been provided in the consolidated financial results of the Group and therefore no separate disclosure on segment information is given in these standalone financial results.

5. On July 10, 2024, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE).

6. On March 13, 2024, the Company and Sanofi India Limited ('SIL') entered into exclusive distribution and promotion agreement for SIL's Cardiovascular products in India. The Company will exclusively distribute and promote the SIL's Cardiovascular (CV) range of products that include well-established brands like Cardace®, Clexane®, Targocid®, Lasix® and Lasilactone®, Due to the said business agreement, the numbers of the quarter and year ended March 31, 2025 are not comparable with the numbers of the quarter and year ended March 31, 2024.

7. The Company has elected to present gains or losses arising from foreign exchange differences as a separate line item on the face of the statement of profit and loss. Accordingly the figures for previous periods which were earlier reported have been reclassified as below:

Particulars	Qua	rter ended 31-March	Year ended 31-March-24			
	Reported	Reclassification	Revised	Reported	Reclassification	Revised
Other income	341,58	64.52	406.10	1,382,57	(120.21)	1,262.36
Other Expenses - Net (gain) / loss on foreign currency transactions		64,52	64.52		(120.21)	(120.21)

8. The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year which were subject to limited review by the Statutory Auditor of the Company. Figures for the quarter ended March 31, 2024 were not subjected to a review by statutory auditors of the Company and are prepared by the management of the Company, reviewed by the Audit Committee and approved by the Board of Directors of the Company.

9. The Board of Directors has recommended a final dividend of Rs. 3 per fully paid up ordinary share of Rs. 10 each for the year ended March 31, 2025, subject to approval by the Shareholders.

For and on behalf of the Board of Directors Encure Pharmaceuticals Limited CIN L24231PN1991PLC024251

Satisti Mente Managing Director & CEO Divi:00118691



Place: Pune Date: 22 May 2025

Chartered Accountants

8th floor, Business Plaza Westin Hotel Campus 36/3-B, Koregaon Park Annex Mundhwa Road, Ghorpadi Pune - 411 001, India Telephone: +91 (20) 6747 7300 Fax: +91 (20) 6747 7100

Independent Auditor's Report

To the Board of Directors of Emcure Pharmaceuticals Limited Report on the audit of the Consolidated Annual Financial Results

Opinion

We have audited the accompanying consolidated annual financial results of Emcure Pharmaceuticals Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), for the year ended 31 March 2025, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

Attention is drawn to the fact that the figures for the quarter ended 31 March 2024, as reported in these consolidated annual financial results have been approved by the Holding Company's Board of Directors, but have not been subjected to audit since the Holding Company got listed during the current year.

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial statements /financial information of the subsidiaries, the aforesaid consolidated annual financial results:

- a. include the annual financial results of the entities mentioned in Annexure I to the aforesaid consolidated annual financial results:
- b. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- c. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of consolidated net profit and other comprehensive income and other financial information of the Group for the year ended 31 March 2025.

Basis for Opinion

ess Plaza

Pune-411001 India

eBCaraces (a

Bus

36/3-B. K

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us along with the consideration of reports of the other auditors referred to in sub paragraph no. (a) of the "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion on the consolidated annual financial results.

Management's and Board of Directors' Responsibilities for the Consolidated Annual Financial Results

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements.

Stee Holding Company's Management and the Board of Directors are responsible for the preparation and 8th Floor,

Registered Office

patrinership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Perthership with LLP Registration No. AAB-8181) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063 Page 1 of 5

Rus

Independent Auditor's Report (Continued)

Emcure Pharmaceuticals Limited

presentation of these consolidated annual financial results that give a true and fair view of the consolidated net profit/ loss and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the respective Management and the Board of Directors of the companies included in the Group are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group is responsible for overseeing the financial reporting process of each company.

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required ath Floor, to draw attention in our auditor's report to the related disclosures in the consolidated annual financial isness Plaza results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the dete of our auditor's report. However, future events or conditions plage 2 of 5

Independent Auditor's Report (Continued) **Emcure Pharmaceuticals Limited**

may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial statements/financial information of the entities within the Group to express an opinion on the consolidated annual financial results. We are responsible for the direction, supervision and performance of the audit of financial statements/financial information of such entities included in the consolidated annual financial results of which we are the independent auditors. For the other entities included in the consolidated annual financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in sub paragraph no. (a) of the "Other Matters" paragraph in this audit report.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated annual financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

Other Matter(s)

8

8th Floor,

ed Acco

ss Plaza

Hotel CampTine Koregaon Park

ornadi 411001

+

The consolidated annual financial results include the audited financial results of 17 subsidiaries and a 3 step down subsidiaries, whose financial statements/ financial information reflects total assets (before consolidation adjustments) of Rs. 40,399.65 million as at 31 March 2025, total revenue (before consolidation adjustments) of Rs. 34,919.98 million and total net profit after tax (net) (before consolidation adjustments) of Rs. 2.921.45 million and net cash outflows (net) (before consolidation adjustments) of Rs 1,463.99 million for the year ended on that date, as considered in the consolidated annual financial results, which have been audited by their respective independent auditors. The independent auditor's reports on financial statements of these entities have been furnished to us by the management.

Our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the reports of such auditors and the procedures performed by us are as stated in paragraph above.

Certain of these subsidiaries are located outside India whose financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been audited by other auditors under generally accepted auditing standards applicable in their respective countries. The Holding Company's management has converted the financial information of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have audited these conversion adjustments made by the Holding Company's management. Our opinion in so far as it relates to the balances and affairs of such subsidiaries located outside India is based on the reports of other auditors and the conversion adjustments prepared by the management of the Holding Company and audited by us.

Co. Our opinion on the consolidated annual financial results is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditors.

consolidated annual financial results include the results for the guarter ended 31 March 2025 Page 3 of 5

Independent Auditor's Report (Continued)

Emcure Pharmaceuticals Limited

being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For BSR&Co.LLP

Chartered Accountants Firm's Registration No.:101248W/W-100022

ablished Abhishek

Partner Membership No.: 062343 UDIN:25062343BMOJBV6126

Pune 22 May 2025

Independent Auditor's Report (Continued) Emcure Pharmaceuticals Limited

Annexure I

List of entities included in consolidated annual financial results.

Sr. No	Name of component	Relationship
1	Emcure Pharmaceuticals Limited ("EPL")	Parent/ Holding Company
2	Zuventus Healthcare Limited	Subsidiary of EPL
3	Gennova Biopharmaceuticals Limited	Subsidiary of EPL
4	Emcure Pharmaceuticals Pty Ltd	Subsidiary of EPL
5	Emcure Nigeria Limited	Subsidiary of EPL
6	Emcure Pharmaceuticals Mena FZ LLC	Subsidiary of EPL
7	Emcure Pharmaceuticals South Africa (Pty) Limited	Subsidiary of EPL
8	Emcure Brasil Farmaceutica Ltda	Subsidiary of EPL
9	Emcure Pharma UK Ltd ("EPUK")	Subsidiary of EPL
10	Emcure Pharma Peru S.A.C.	Subsidiary of EPL
11	Emcure Pharma Mexico S.A. DE C.V.	Subsidiary of EPL
12	Marcan Pharmaceuticals Inc. ("MPI")	Subsidiary of EPL
13	Emcure Pharma Chile SpA	Subsidiary of EPL
14	Lazor Pharmaceuticals Limited	Subsidiary of EPL
15	Emcure Pharma Philippines Inc.	Subsidiary of EPL
16	Emcure Pharmaceuticals Dominicana S.A.S	Subsidiary of EPL
17	Emcutix Biopharmaceuticals Limited	Subsidiary of EPL
18	Tillomed Laboratories Ltd	Subsidiary of EPUK
19	Tillomed Pharma GmbH	Subsidiary of EPUK
20	Laboratories Tillomed Spain SLU	Subsidiary of EPUK
21	Tillomed Italia S.R.L.	Subsidiary of EPUK
22	Tillomed France SAS	Subsidiary of EPUK
23	Tillomed Malta Ltd.	Subsidiary of EPUK
24	Mantra Pharma Inc.	Subsidiary of MPI



Page 5 of 5



			₹in	million (unless of	therwise stated
Particulars		Quarter ended		Year e	nded
	31-Mar-25	31-Dec-24	31-Mar-24	31-Mar-25	31-Mar-24
	Refer note 9	Unaudited	Refer note 9	Audited	Audited
Income:					
Revenue from operations	21,162.45	19,626.30	17,713.56	78,959.97	66,582.51
Other income (Refer note 8)	44.53	38.96	124.17	672.61	438.05
Total income	21,206.98	19,665.26	17,837.73	79,632.58	67,020.56
Expenses:					
Cost of materials consumed	4,038.73	3,998.25	3,727.84	15,269.01	13,331.26
Purchases of stock-in-trade	5,718.56	4,289.34	3,693.94	18,832.35	13,324.83
Changes in inventories of finished goods, work-in-progress and stock-in-	(836.19)	(460.32)	(711.85)	(2,635.33)	(1,901.92
trade	(· · · · · · /	((-/	(1)
Employee benefit expenses	3,733.65	3,669.33	3,385.12	14,462.92	12,920.80
Depreciation and amortisation expense	968.37	968.06	905.64	3,841.28	3,124.07
Finance costs	390.25	317.78	654.86	1,757.84	2,371.47
Other expenses	4,608.46	4,512.28	4,504.99	18,342.48	16,610.31
Net (gain) / loss on foreign currency transactions (Refer note 8)	(124.76)	71.35	6.78	(55.24)	(131.85
Total expenses	18,497.07	17,366.07	16,167.32	69,815.31	59,648.97
Profit before exceptional items and tax	2,709.91	2,299.19	1,670.41	9,817.27	7,371.59
		£,233.13			
Exceptional items (refer note 3)	103.78		1,37	103.78	99.31
Profit before tax	2,606.13	2,299.19	1,669.04	9,713.49	7,272.28
Tax expense	045 53	500.04	205.00	2 024 57	2 000 20
Current tax	915.53	589.31	286.89	2,921.57	2,096.39
Deferred tax	(281.77)	148.97	171.98	(282.75)	(99.86
Fotal tax expenses	633.76	738.28	458.87	2,638.82	1,996.53
Profit for the period/year	1,972.37	1,560.91	1,210.17	7,074.67	5,275.75
Other comprehensive income					
a) Other comprehensive income/(loss) not to be reclassified to profit	(29.01)	(2.10)	(64.60)	(36.17)	(88.25
- Income tax on above	7.73	1.00	2.36	9.74	22.28
	7.75	1.00	2,50	5.74	22.20
b) Other comprehensive income/(loss) to be reclassified to profit or	305.53	(581.87)	(200.07)	341.35	222.25
DSS					
Other comprehensive income/(loss) for the period/year	284.25	(582.97)	(262.31)	314.92	156.28
otal comprehensive income for the period/year	2,256.62	977.94	947.86	7,389.59	5,432.03
Profit attributable to:					
Owners of the Holding company	1,889.57	1,537.22	1,151.68	6,813.32	4,981.83
Non-controlling interests	82.80	23.69	58.49	261.35	4,581.85
Non-controlling interests	82,80	23,03	56,45	201.55	293.92
Other comprehensive income attributable to:					
Owners of the Holding company	286.60	(582.97)	(260.06)	317.41	158.81
Non-controlling interests	(2.35)	-	(2.25)	(2.49)	(2.53
Total comprehensive income attributable to:			1		
Owners of the Holding company	2,176.17	954.25	891.62	7,130.73	5,140.64
Non-controlling interests	80.45	23.69	56.24	258.86	291,39
arnings per share (not annualised for the Quarter and nine months					
nded):					
asic	9.97	8.12	6.36	36.43	27.54
iluted	9.97	8.12	6.36	36.43	27.54
aid up equity share capital [Face value per share: Rs.10]	1,894.83	1,894.32	1,811.52	1,894.83	1,811.52
are ab educe online cohicultinger sugre her sugre usitol	1,004.00	1,004,02	20.1102	1,004.00	1,011.02
ther equity				42,567.03	27,711.31

Emcure Pharmaceuticals Limited Building A-202, Ganga Osian Square, Wakad, Pune - 411 057, Maharashtra Andia. Phone : +91 20 - 35040000 / 66770000



		₹ in millio
Particulars	31-Mar-25 Audited	31-Mar-24 Audited
A. ASSETS		
(1) Non-current assets		
Property, plant and equipment	19,535.99	19,485.7
Capital work-in-progress	1,240.64	1,323.4
Right-of-use assets	3,494.58	3,162.8
Goodwill	3,677,75	3,786.8
Other Intangible assets	5,258.98	4,809.9
Intangible assets under development	5,258.98	4,809.5
Financial assets i) Investments	193,36	184.2
ii) Other non current financial assets	394.72	407.6
Deferred tax assets (pot)	1 100 00	067.0
Deferred tax assets (net) Income tax assets (net)	1,109.90 940.38	967.9 872.4
Other non-current assets	388.93	193.5
fotal non- current assets	36,768.59	35,462.4
(2) Current assets		
Inventories	19,318.12	15,251,0
Financial assets		
i) Investments	760.43	2,996.9
ii) Trade receivables	20,022.43	18,588.0
iii) Cash and cash equivalents	1,555.36	1,690.0
iv) Bank balances other than (iii) above	97.61	634.0
v) Other current financial assets	525.21	689.4
Other current assets	3,279.48 45,558.64	2,695.7 42,544.9
Assets held for sale		54.2
otal current assets	AE 250 CA	
	45,558.64	42,599.1
OTAL ASSETS	82,327.23	78,061.6
EQUITY AND LIABILITIES Equity		
Equity share capital	1,894.83	1,811.5
Other equity	42,567.03	27,711.3
Equity attributable to owners of the Holding company	44,461.86	29,522.8
Non-controlling interest	1,953.68	1,694.8
otal equity	46,415.54	31,217.6
LIABILITIES		
(1) Non-current liabilities		
Financial liabilities		
i) Borrowings	1,899.37	7,665.9
ii) Lease Liabilities	2,573.17	2,157.4
iii) Other non current financial liabilities	2,935.40	2,945.7
Provisions	475.78	433.2
Deferred tax liabilities (net)	1,200.33	1,374.2
Other non-current liabilities	144.93	162.6
tal non-current liabilities	9,228.98	14,739.2
(2) Current liabilities		
Financial liabilities		40.000
i) Borrowings	5,417.67	13,207.1
ii) Lease Liabilities	337,28	319.1
iii) Trade payables		
Total outstanding dues of micro and small enterprises	322.87	169.1
Total outstanding dues to others	14,472.94	12,924.5
iv) Other current financial liabilities	3,258.00	3,044.2
	1 205 72	
Other current liabilities	1,205.79	1,448.6
Provisions	545.12	457.3
Current tax liabilities (net)	1,123.04	534.4
tal current liabilities	26,682.71	32,104.7
tal liabilities	35,911.69	46,843.9



Particulars	Year ended 31-Mar-25 Audited	₹ in milli Year ended 31-Mar-24 Audited
A. Cash flows from operating activities:	Addited	Addited
Profit before tax	9,713.49	7,272.2
A limburgh for		
Adjustment for: Depreciation and amortisation expense	3,841.28	3,124.0
Finance costs	1,757.84	2,371.4
Employee share-based expense	19.89	39.6
Interest income from banks and others	(90.44)	(207.5
(Profit) / Loss on sale of property, plant and equipment	(382.35)	(71.9
Gain on termination of leases Profit on sale of investment	(67.77) (54.77)	(15.6 (23.1
Net gain on financial assets measured at FVTPL	(3.27)	(2.1
Effect of exchange rate changes	494.71	216.7
	15,228.61	12,703.7
Working capital adjustments: - (Increase)/ decrease in inventories	(4,067.12)	(267.6
- (Increase)/ decrease in trade receivables	(1,434.39)	(1,506.0
- (Increase)/ decrease in other financial assets	175.94	(156.0
- (Increase)/ decrease in other assets	(672.96)	259.9
- Increase/ (decrease) in trade payables	1,702.14	1,542.6
 Increase/ (decrease) in other financial liabilities Increase/ (decrease) in other liabilities 	12.37 (52.91)	272.3 289.8
- Increase/ (decrease) in provisions	93.95	70.0
	(4,242.98)	505.1
Cash generated from operating activities	10,985.63	13,208.9
Income tax paid (net of refunds)	(2,468.58) 8,517.05	(2,236.5
Net cash generated from operating activities (A)	8,517.05	10,572.4
B. Cash flows from investing activities		(*)
Purchase of property, plant and equipment, capital work-in-progress and Leasehold land rights	(2,217.67)	(2,757.7
Purchase of intangible assets and intangible assets under development Proceeds from sale of property, plant and equipment and transfer of Leasehold land rights	(1,851.60) 306.01	(313.6 107.8
Advance received against assets held for sale		207.5
Investment in financial instruments	(86.56)	
Investment in mutual funds and non convertible debentures	(6,969.75)	(8,990.0
Proceeds from sale of mutual funds and redemption of non convertible debenture	9,159.52	6,123.10
Consideration paid on acquisition of Subsidiary, net of cash acquired Interest received from banks and others	231.44	(3,450.7) 179.4
Term deposit placed	(213.18)	(1,002.8)
Term deposit matured	701.78	2,771.7
Net cash used in investing activities (B)	(940.01)	(7,125.1
C. Cash flows from financing activities		
Proceeds from issue of shares (net of offer expenses)	7,792.28	76.60
Payment on account of settlement of Employee stock options	2	(202.30
Repayment of long-term borrowings	(8,833.00)	(4,822.9
Proceeds from long-term borrowings Repayments of short-term borrowings (net)	(5,224.99)	5,474.29 1,025.44
Interest paid	(1,286.77)	(2,081.83
Repayment of lease liabilities	(587.09)	(486.8)
Dividend paid by holding company	2	(542.55
Dividend paid to non controlling interest	-	(81.9)
Net cash used in financing activities (C)	(8,139.57)	(1,642.06
Net increase / (decrease) in cash and cash equivalents (A+B+C)	(562.53)	2,205.22
Cash and cash equivalent as at the beginning of the period	439.91	(1,745.29
Effect of exchange rate fluctuations on cash and cash equivalent	(20.49)	(20.0)
Cash and cash equivalent as at period end	(143.11)	459.9.
Components of cash and cash equivalent:		
Cash on hand Relances with bank in surrout accounts	1.06	1.6
Balances with bank in current accounts Balances with bank in cash credit accounts	1,182.68 90.40	977.68 104.66
Demand deposits (with original maturity of less than 3 months)	281.22	606.05
Bank overdrafts used for cash management purpose	(1,698.47)	(1,250.09
Total cash and cash equivalent*	(143.11)	439.91
ash and cash equivalent includes bank overdrafts that are repayable of demand and form an integral p	art of the Group's cash mana	gement.
PUNE		

Emcure Pharmaceuticals Limited

Statement of Audited Consolidated Financial Results for the quarter and year ended March 31, 2025

Notes:

1. These audited consolidated financial results of the Holding Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 ("the Regulations"). The said audited consolidated financial results represent the results of Emcure Pharmaceutical Limited ("Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter and year ended March 31, 2025.

2. The above audited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Holding Company at their respective meetings held on May 22, 2025. The results are subjected to Limited Review by the statutory auditors of the Holding Company in terms of Regulation 33 of The Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR), as amended. The statutory auditors have expressed an unmodified opinion on above audited consolidated financial results.

3. During the quarter ended March 31, 2024 and year ended March 31, 2024, consultancy fees paid in relation to acquisition of Canadian entities has been classified as exceptional item. During the quarter ended March 31, 2025 and year ended March 31, 2025, consultancy fees paid in relation to Canada Drug Pricing Matter and amounts paid towards legal settlements have been classified as exceptional items.

4. The Group is primarily engaged in manufacturing and trading of pharmaceuticals products. Accordingly, the Group has only one reportable segment 'Pharmaceuticals' and disclosures as per Ind AS 108 "Operating Segments" are not applicable.

5. On July 10, 2024, the equity shares of the Holding Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE).

6. On November 06, 2023, Marcan Pharmaceuticals Inc. (subsidiary of the Holding Company) through its subsidiary Mantra Pharma Inc. (erstwhile known as "Québec Inc.") acquired business of Mantra Group by purchasing 100% of issued and outstanding shares of Mantra group for upfront cash consideration plus additional consideration payable to the selling shareholders of Mantra in the form of preference shares. Due to the acquisition, the numbers of the year ended March 31, 2025 are not comparable to the year ended March 31, 2024.

7. On March 13, 2024, the Holding Company and Sanofi India Limited ('SIL') entered into exclusive distribution and promotion agreement for SIL's Cardiovascular products in India. The Holding Company will exclusively distribute and promote the SIL's Cardiovascular (CV) range of products that include well-established brands like Cardace[®], Clexane[®], Targocid[®], Lasix[®] and Lasilactone[®]. Due to the said business agreement, the numbers of the quarter and year ended March 31, 2025 are not comparable with the numbers of the quarter and year ended March 31, 2024.

8. The Group has elected to present gains or losses arising from foreign exchange differences as a separate line item on the face of the statement of profit and loss. Accordingly the figures for previous periods have been reclassified as below:

Particulars	Qu	arter ended 31-Mar	-24	Year ended 31-Mar-24			
	Reported	Reclassification	Revised	Reported	Reclassification	Revised	
Other income	117.39	6.78	124.17	569.90	(131.85)	438.05	
Other Expenses : Net (gain) / loss on foreign currency transactions	<u></u>	6.78	6.78	12	(131.85)	(131.85)	

9. The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year which were subject to limited review by the Statutory Auditor of the Holding Company, Figures for the quarter ended March 31, 2024 were not subjected to a review by statutory auditors of the Holding Company and are prepared by the management of the Holding Company, reviewed by the Audit Committee and approved by the Board of Directors of the Holding Company.

10. The Board of Directors of the Holding Company has recommended a final dividend of Rs. 3 per fully paid up ordinary share of Rs. 10 each for the year ended March 31, 2025, subject to approval by the Shareholders.

For and on behalf of the Board of Directors Enjoure Pharmaceuticals Limited CINTL24231PN1981PLC024251

Satish Wiehta Mapaging Director & CEO DW: 00118691



Place: Pune

Place: Pune Date: 22 May 2025

Annexure - B



Emcure Pharmaceuticals Achieves Robust Q4FY25 Performance with 19% Revenue Growth and 63% Profit After Tax Growth

- Revenue from operations at Rs 2,116Cr, up 19.5% YoY
- EBITDA margins at 18.4% with EBITDA up 25.2% YoY
- PAT at 197Cr, up 63.0% YoY
- Domestic business sales at 929Cr, up 24.8% YoY
- International business sales at 1,187Cr, up 15.6% YoY
- The Board has proposed a final dividend of Rs 3/- per share

Pune, May 22, 2025: Emcure Pharmaceuticals (BSE:544210, NSE: EMCURE) today announced its consolidated financial results for the quarter and year ended March 31st, 2025.

The quarter saw strong performance across both our Domestic and International businesses. Emcure's Domestic business grew by 24.8% YoY led by our Women's Health and Cardio franchises and further aided by our new focus areas of Dermatology and OTC. The International business registered a growth of 15.6% led by a robust 39.3% growth in the Rest of the World segment. Our Canada business continues to perform well with Mantra now fully integrated. In Europe we recently acquired a portfolio of products and secured key regulatory approvals which will aid growth going forward.

Commenting on the results, Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, "Emcure delivered a very strong performance in Q4 with all our businesses segments contributing to growth. Over the past year we have effectively executed our strategies across both Domestic and International markets. On the Domestic side we have expanded our covered market and built a strong product pipeline of upcoming launches. In the International markets we are seeing approvals for our differentiated product offerings. Moving forward, while we continue to drive growth, our key priorities will be improving margins through new product launches and operating efficiencies."

Revenue break-up:

Rs Cr	4Q25	4Q24	YOY%	3Q25	QOQ%	FY25	FY24	YOY%
Revenue from	2,116	1,771	19.5%	1,963	7.8%	7,896	6,658	18.6%
operations								
Domestic	929	744	24.8%	888	4.5%	3,660	3,144	16.4%
International	1,187	1,027	15.6%	1,075	10.5%	4,236	3,514	20.5%
EM	481	345	39.3%	365	31.6%	1,510	1,180	27.9%
EU	396	389	1.7%	358	10.6%	1,474	1,411	4.4%
СА	310	293	6.2%	352	-11.5%	1,252	923	35.7%

Emcure[®]

Performance Summary (Consolidated)

Rs Cr	4Q25	4Q24	YOY%	3Q25	QOQ%	FY25	FY24	ΥΟΥ%
Revenue from operations	2,116	1,771	19.5%	1,963	7.8%	7,896	6,658	18.6%
Material Cost	892	671	33.0%	783	14.0%	3,147	2,475	27.1%
Gross Profit	1,224	1,100	11.2%	1,180	3.7%	4,749	4,183	13.5%
Gross Profit Margins	57.8%	62.1%		60.1%		60.1%	62.8%	
Employee Costs	373	339	10.3%	367	1.8%	1,446	1,292	11.9%
Other expenses	461	450	2.3%	451	2.1%	1,834	1,661	10.4%
EBITDA	390	311	25.2%	362	7.8%	1,469	1,230	19.4%
EBITDA Margins	18.4%	17.6%		18.4%		18.6%	18.5%	
Other Income	4	12		4		67	43	
Depreciation and Amortisation	97	91		97		384	312	
Finance Costs inc. Forex	26	65		39		171	224	
Exceptional Items	10	0		0		10	10	
Profit Before Tax (PBT)	261	167	56.1%	230	13.3%	971	727	33.6%
Тах	64	46		74		264	199	
Profit After Tax (PAT)	197	121	63.0%	156	26.4%	707	528	34.1%
PAT Margins	9.3%	6.8%		8.0%		9.0%	7.9%	

About Emcure Pharmaceuticals Ltd:

Emcure Pharmaceuticals Ltd. (EPL) is a leading Indian pharma company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Known for its commitment to innovation, quality, and patient-centricity, Emcure is an R&D driven company that develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Established in 1981, EPL is ranked as the 12th largest pharma company in India in terms of Domestic Sales for MAT June 2024. Emcure is present in 70+ countries globally including Europe and Canada.

Contact:

Media

corpcomm@emcure.com

Investor Relations

investor.relations@emcure.com

Emcure[®]

Details of the Earnings Call:

- Date: Thursday, May 22, 2025
- Time: 3:30 p.m. 4:30 p.m. (IST)
- Dial-In Numbers:
 - Universal Access: <u>+91 22 6280 1220</u> / <u>+91 22 7115 8122</u>
 - o USA: 1 866 746 2133
 - o UK: 0 808 101 1573
 - Singapore: 800 101 2045
 - Hong Kong: 800 964 448

Annexure-C

Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Sr. No.	Particulars	Information
1	Reason for change viz. appointment re-appointment, resignation, removal, death or otherwise	Re-appointment as Whole-time Director of the Company.
2	Date of appointment/ re-appointment/ cessation (as applicable) & term of appointment/ re-appointment	Re-appointment with effect from August 28, 2025 for a further period of one (1) year, subject to approval of Members of the Company.
3	Brief profile (in case of appointment);	 Dr. Mukund Gurjar has been associated with the Company since July 23, 2001, as Director of the Company. Dr. Gurjar holds a bachelor's degree in science, a master's degree in science and qualified as a doctor of philosophy in the faculty of science from the Nagpur University. He also holds a degree of doctor of philosophy from the Queen Elizabeth College, University of London Prior to joining our Company, he was working with the National Chemical Laboratory, Pune for 24 years. He has received a certificate of appreciation in recognition of 17 years of his valued services as an editorial advisory board member for Organic Process Research & Development, American Chemical Society. Dr. Gurjar brings technical & industrial expertise to the Board as well as the Company. He has been an Executive Director and Chief Scientific Officer of the Company.
4	Disclosure of relationships between Directors (in case of appointment of a director).	Dr. Gurjar is not related to any director on the Board of the Company.



Emcure Pharmaceuticals Limited



Annexure - D

Appointment of M/s SVD & Associates as Secretarial Auditors

Sr. No.	Particulars	Information
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment of M/s. SVD & Associates, Company Secretaries, Pune, a Peer Reviewed Firm of Company Secretaries in Practice (UIN P2013MH031900 and Peer Review No. 6357/2025), as Secretarial Auditors of the Company.
2.	Date of appointment/ re-appointment/cessation (as applicable) & term of appointment/ re-appointment;	The Board of Directors at their meeting held today i.e. on May 22, 2025, have approved the appointment of M/s. SVD & Associates, Company Secretaries, Pune, as Secretarial Auditors, for a term of 5 (Five) consecutive years commencing from the FY 2025-26, subject to approval by the Members at the ensuing Annual General Meeting of the Company.
3.	Brief Profile (in case of appointment);	M/s. SVD & Associates, Company Secretaries, Pune was formed in 2014 by Professionals of varied skill set, to bring out synergy in corporate legal and corporate advisory services with a pivotal role in Secretarial Audit. Catering to a wide range of clients, including a large number of listed and multinational companies, its strength is its team of qualified, experienced and trained professionals who treasure the value of diligence and knowledge. The firm is peer reviewed in terms of the peer review guidelines issued by the ICSI.
4.	Disclosure of relationships between Directors (in case of appointment of a director)	Not Applicable



Emcure Pharmaceuticals Limited

Annexure E

Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Sr. No	Particulars	Information
a)	Name of the target entity, details in brief such as size, turnover etc.	Name: Emcure Generics Private LimitedProposedAuthorizedShareCapital:Rs. 10,00,00,000/- (Rupees Ten Crores only)ProposedPaid-upShareCapital:Rs. 1,00,000/- (Rupees One Lakh only)Turnover: Not Applicable, as the entity is yetto be incorporated.
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The proposed entity would be a wholly-owned Subsidiary (WoS) of the Company and hence once incorporated, the WoS will be a related party of the Company and other subsidiaries. Save and except what is mentioned above, the Promoters / Promoter Group / Group Companies are not interested in the transaction.
c)	Industry to which the entity being acquired belongs	Pharmaceuticals
d)	Objects and impacts of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	WoS is being incorporated to manufacture, promote, sale and distribute pharmaceuticals and other related product(s).
e)	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
f)	Indicative time period for completion of the acquisition	Not Applicable
g)	Nature of consideration - whether cash consideration or share swap and details of the same	100% subscription to initial paid-up share capital of Rs. 1,00,000/- (Rupees One Lakh only) is in cash.

Emcure Pharmaceuticals Limited

RE

h)	Cost of acquisition or the price at which the shares are acquired	At face value of Rs.10/- per share.
i)	Percentage of shareholding/ control acquired and/ or number of shares acquired	100% subscription to the share capital of the proposed WoS.
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Not applicable since the proposed WoS is yet to be incorporated.



Emcure Pharmaceuticals Limited